Olmos Pablo Roberto, Borzone Gisella Rosa, Olmos Roberto Ignacio, Valencia Claudio Nicolás, Bravo Felipe Andrés, Hodgson María Isabel, Belmar Cristián Gastón, Poblete José Andrés, Escalona Manuel Orlando, Gómez Bernardita
Departments of Nutrition, Diabetes and Metabolism, College of Engineering, Pontificia Universidad Católica de Chile, Santiago, Chile.
J Obstet Gynaecol Res. 2012 Jan;38(1):208-14. doi: 10.1111/j.1447-0756.2011.01681.x. Epub 2011 Nov 9.
Good glycemic control in gestational diabetes mellitus (GDM) seems not to be enough to prevent macrosomia (large-for-gestational-age newborns). In GDM pregnancies we studied the effects of glycemic control (as glycosylated hemoglobin [HbA1c]), pre-pregnancy body mass index (PP-BMI) and gestational weight gain per week (GWG-W) on the frequency of macrosomia.
We studied 251 GDM pregnancies, divided into two groups: PP-BMI<25.0kg/m(2) (the non-overweight group; n=125), and PP-BMI≥25.0kg/m(2) (the overweight group; n=126). A newborn weight Z-score>1.28 was considered large-for-gestational-age. Statistical analysis was carried out using the Student's t-test and χ(2) -test, receiver-operator characteristic curves and linear and binary logistic regressions.
Prevalence of macrosomia was 14.9% among GDM (n=202/251, 88.4%) with good glycemic control (mean HbA1c<6.0%), and 28.1% in those with mean HbA1c≥6.0% (n=49/251, P<0.025). Macrosomia rates were 10.4% in the non-overweight group and 24.6% in the overweight group (P=0.00308), notwithstanding both having similar mean HbA1c (5.48±0.065 and 5.65±0.079%, P=0.269), and similar GWG-W (0.292±0.017 and 0.240±0.021kg/week, P=0.077). Binary logistic regressions showed that PP-BMI (P=0.012) and mean HbA1c (P=0.048), but not GWG-W (P=0.477), explained macrosomia.
Good glycemic control in GDM patients was not enough to reduce macrosomia to acceptable limits (<10% of newborns). PP-BMI and mean HbA1c (but not GWG-W) were significant predictors of macrosomia. Thus, without ceasing in our efforts to improve glycemic control during GDM pregnancies, patients with overweight/obesity need to be treated prior to becoming pregnant.
妊娠期糖尿病(GDM)患者良好的血糖控制似乎不足以预防巨大儿(大于胎龄儿)。在患有GDM的孕妇中,我们研究了血糖控制(以糖化血红蛋白[HbA1c]表示)、孕前体重指数(PP-BMI)和每周孕期体重增加(GWG-W)对巨大儿发生率的影响。
我们研究了251例GDM孕妇,分为两组:PP-BMI<25.0kg/m²(非超重组;n=125)和PP-BMI≥25.0kg/m²(超重组;n=126)。新生儿体重Z评分>1.28被视为大于胎龄。采用学生t检验和χ²检验、受试者工作特征曲线以及线性和二元逻辑回归进行统计分析。
在血糖控制良好(平均HbA1c<6.0%)的GDM患者中(n=202/251,88.4%),巨大儿的发生率为14.9%,而平均HbA1c≥6.0%的患者中这一比例为28.1%(n=49/251,P<0.025)。非超重组巨大儿发生率为10.4%,超重组为24.6%(P=0.00308),尽管两组的平均HbA1c相似(5.48±0.065和5.65±0.079%,P=0.269),且GWG-W也相似(0.292±0.017和0.240±0.021kg/周,P=0.077)。二元逻辑回归显示,PP-BMI(P=0.012)和平均HbA1c(P=0.048),而非GWG-W(P=0.477),可解释巨大儿的发生情况。
GDM患者良好血糖控制不足以将巨大儿发生率降低至可接受水平(<10%的新生儿)。PP-BMI和平均HbA1c(而非GWG-W)是巨大儿的重要预测因素。因此,在我们继续努力改善GDM孕期血糖控制的同时,超重/肥胖患者在怀孕前需要接受治疗。